ACTIVE PHARMA INGREDIENTS (API) [AZITHROMYCIN, ALPHA LIPOIC ACID, PREGABLIN, NAPROXEN, KETOPROFEN]

The project report includes Present Market Position and Expected Future Demand, Market Size, Statistics, Trends, SWOT Analysis and Forecasts. Report provides a comprehensive analysis from industry covering detailed reporting and evaluates the position of the industry by providing insights to the SWOT analysis of the industry.

We can prepare PROJECT REPORT as per your INVESTMENT PLAN for BANK LOAN REQUIREMENT and INDUSTRY ANALYSIS. All reports are prepared by highly qualified consultants and verified by a panel of experts.

Have Query? Click Here to Chat
Industry Expert is Online, Chat with him for more detail.

The Active Pharmaceutical Ingredient Industry is the organ by which active pharmaceutical ingredients are manufactured from raw materials through both chemical and physical means. Depending on the complexity of the molecule required, synthesis of APIs might need multi-step complex chemistry utilizing a range of processing technologies.

The leading manufacturer of APIs today is TAPI (Teva Active Pharmaceutical Ingredients). Specializing in range of API-related fields, TAPI works in areas such as chemical synthesis, fermentation, and chromatography and plant extraction and now has the industry’s largest portfolio of over 300 API products. In 2011 alone they achieved third-party sales of around $750 million.

Dr. Reddy’s is another leading manufacturer with 60 APIs for drug use, diagnostic kits and biotechnology products. Aurobindo and Cipla manufacture 200 APIs each, exporting their products to well over 200 countries worldwide. Other notable manufacturers are Sandoz-Lek-Biochemie, Ranbaxy, Matrix and Sun.

APIs are commonly referred to as ‘bulk pharmaceuticals’ and are in fact usually made in places at quite a distance to where tablets, suspensions and liquids are manufactured. Today, the greatest concentrations of API manufacturers are located around Asia, specifically in India and China.

This has led to more and more companies to outsource API manufacturing to such places, which has the main benefit of eliminating the need to invest in highly expensive equipment and infrastructure – which on top of everything can also be complicated to install and maintain. A good example can be found with AstraZeneca, who manufacture 85% of its APIs but are currently in the process of withdrawing from all API production in favor of outsourcing.

Regardless of where the active pharmaceutical ingredient is made, companies must adhere to strict safety and quality standards set by the country where it will be used. So those APIs manufactured in China or India for use in the United States must still be inspected and licensed by the FDA. Similarly, if the API is intended for use in Europe, they would need to meet regulations set by the European Medicines Agency. Regular inspection outside the country of use however can prove difficult with counterfeiting and contamination being high on the list of various agencies’ concerns. For instance, since 2008, the FDA has considerably increased its overseas staff as a way of attempting to eliminate these problems. As a result, countries such as India have gained their foothold in the global market and now have around 75 FDA-approved manufacturing facilities for API synthesis.

Today there are more and more calls for API manufacturers to go green – that is to say, to reduce the waste they produce. Every year, large pharmaceutical manufacturers can produce anywhere from 3000 to 5000 tons of hazardous waste each. If one were to ask any reputable API manufacturer how they would like to improve the process, they’d likely say to make the reactions faster, or to make them cheaper. Ironically the first steps in reducing waste from API synthesis would be to reduce the number of reactions required to produce a given molecule. Therefore though the goal may be different, the means turn out to be the same as fewer reactions mean less solvent to dispose of. Another step in going green is to find different solvents and catalysts that are not only more efficient, but are also better for the environment.

Naproxen is a nonsteroidal anti-inflammatory drug (NSAID).

Naproxen is a pain medication that relieves inflammation and joint stiffness. Other NSAIDs in the same medication class include acetylsalicylic acid, diclofenac, ibuprofen, and meloxicam.

Naproxen works by blocking the enzyme that produces prostaglandins. Prostaglandins play an essential role in inflammation. The body produces them at the site of injured tissue, and they cause redness, heat, swelling, and pain.

Naproxen is available as naproxen or naproxen sodium. The major difference between naproxen and naproxen sodium is that naproxen sodium is more rapidly absorbed.

The body reaches peak levels of naproxen in 2–4 hours and naproxen sodium in 1–2 hours, meaning that it absorbs naproxen sodium faster than regular naproxen.

Alpha-lipoic acid

Generic name: alpha-lipoic acid (AL fa lye POE ik AS id)

Brand name: Alpha Lipoic Acid, Alpha-Lipoic-Acid-300, Alpha Lipoic

Dosage forms: oral capsule (100 mg; 200 mg; 300 mg; 600 mg); oral tablet (100 mg; 300 mg; 50 mg)

Drug class: Nutraceutical products

Alpha-lipoic acid is an antioxidant also known as Acetate Replacing Factor, ALA, Biletan, Lipoicin, Thioctan, and many other names.

Alpha-lipoic acid is a naturally occurring fatty acid that can be found in many foods such as yeast, spinach, broccoli, potatoes, and organ meats such as liver or kidney.

Alpha-lipoic acid has been used in alternative medicine as a possibly effective aid in weight loss, treating diabetic nerve pain, healing wounds, lowering blood sugar, improving skin discoloration caused by vitiligo, and decreasing complications of coronary artery bypass graft (CABG) surgery. Alpha-lipoic acid may have been combined with other plants or extracts in a specific preparation to treat these conditions.

Alpha-lipoic acid has also been used to treat rheumatoid arthritis, Alzheimer’s disease, alcoholic liver problems, altitude sickness, heart-related nerve problems, HIV-related brain problems, or eye problems caused by diabetes. However, research has shown that alpha-lipoic acid may not be effective in treating these conditions.

Azithromycin

Generic name: azithromycin (a ZITH roe MYE sin)

Brand name: Azasite, Azithromycin 3 Day Dose Pack, Azithromycin 5 Day Dose Pack, Zithromax, Zithromax TRI-PAK, Zithromax Z-Pak, Zmax

Drug class: Macrolides

Azithromycin is an antibiotic that fights bacteria.

Azithromycin is used to treat many different types of infections caused by bacteria, such as respiratory infections, skin infections, ear infections, eye infections, and sexually transmitted diseases.

Azithromycin may also be used for purposes not listed in this medication guide.

Ketoprofen

Generic name: ketoprofen (kee toe PROE fen)

Brand name: Orudis, Oruvail, Actron, Orudis KT

Dosage forms: oral capsule (25 mg; 50 mg; 75 mg); oral capsule, extended release (200 mg)

Drug class: Nonsteroidal anti-inflammatory drugs

Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat pain or inflammation caused by arthritis.

The ketoprofen regular capsule is also used to treat mild to moderate pain, or menstrual pain.

Only ketoprofen extended-release capsules are used for treating arthritis. This form of ketoprofen will not work fast enough to treat acute (immediate) pain.

Pregabalin

Generic name: pregabalin (pre GAB a lin)

Brand name: Lyrica, Lyrica CR

Dosage forms: oral capsule (100 mg; 150 mg; 200 mg; 225 mg; 25 mg; 300 mg; 50 mg; 75 mg); oral solution (20 mg/mL); oral tablet, extended release (165 mg; 330 mg; 82.5 mg)

Drug class: Gamma-aminobutyric acid analogs

Pregabalin is an anti-epileptic drug, also called an anticonvulsant. It works by slowing down impulses in the brain that cause seizures. Pregabalin also affects chemicals in the brain that send pain signals across the nervous system.

Pregabalin is used to treat pain caused by fibromyalgia, or nerve pain in people with diabetes (diabetic neuropathy), herpes zoster (post-herpetic neuralgia), or spinal cord injury.

Pregabalin is also used with other medications to treat partial onset seizures in adults and children who are at least 1 month old.

Description

INTRODUCTION
ALPHA-LIPOIC ACID
AZITHROMYCIN
KETOPROFEN
PREGABALIN
CHEMISTRY AND MANUFACTURERS OF API
CHEMISTRY
MANUFACTURERS
CARBIDOPA API
DILTIAZEM
PRECAUTIONS
GEMFIBROZIL API
THERAPEUTIC EFFECTS
PRECAUTIONS AND TOXICITIES
DRUG INTERACTIONS
AZITHROMYCIN API
TREATMENT
MECHANISM OF ACTION
SIDE EFFECTS
ACTIVE PHARMA INGREDIENTS
APIS ARE GENERALLY MANUFACTURED THROUGH A VARIETY OF PROCESSES THAT INCLUDE:
MARKET OVERVIEW OF API
KEY MARKET ANALYSIS
GLOBAL OVERVIEW OF API
MARKET OF INDIAN PHARMACEUTICAL INDUSTRY
COMPOSITION OF INDIAN PHARMA MARKET
PHARMA EXPORT TO CONTINUE WITNESSING POSITIVE GROWTH
CHALLENGES FACED BY INDIAN API INDUSTRY
STRICTER IMPLEMENTATION OF POLLUTION CONTROL NORMS
INTERPRETATION OF DPCO,
NO TAX INCENTIVES, HIGHER UTILITIES AND BORROWING COST
LACK OF MEGA BULK DRUG PARKS
ISSUES FACED BY FERMENTATION INDUSTRY
RECOMMENDATIONS
FASTER ENVIRONMENT CLEARANCE
ENCOURAGE MANUFACTURING BY PROVIDING A FISCAL STIMULUS FOR APIS AND INTERMEDIATES
FOR FERMENTATION PRODUCTS
RECOMMENDATIONS – IMMEDIATE
ACCOMMODATIVE PRICING POLICY UNDER DPCO,
FINANCIAL INCENTIVES
RECOMMENDATIONS – LONG TERM
INDUSTRY–ACADEMIA INITIATIVES
FACILITATE ALTERNATIVE SOURCES OF IMPORT
USES AND APPLICATION OF NAPROXEN
DOSAGE AND FORM OF NAPROXEN
MILD TO MODERATE PAIN
OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS
ACUTE GOUT ATTACKS
JUVENILE RHEUMATOID ARTHRITIS
HEADACHES
MANUFACTURING PROCESS OF AZITHROMYCIN
CHEMICAL REACTION
MATERIAL OR MASS BALANCE
MANUFACTURING PROCESS OF PREGABALIN
STAGE- I
STAGE-II
STAGE-III
PROCESS FLOW DIAGRAM
MATERIAL BALANCE OF PREGABALIN
STAGE-I
STAGE-II
STAGE-III
MANUFACTURING PROCESS OF NAPROXEN
STAGE-I
STAGE-II
STAGE-III
STAGE-IV
STAGE-V
STAGE-VI
STAGE-VII
PROCESS FLOW DIAGRAM
RAW MATERIALS
MANUFACTURING PROCESS OF ALPHA LIPOIC ACID
STAGE-1
STAGE-II
STAGE-III
MANUFACTURING PROCESS OF KETOPROFEN
STEP-I
STEP-II
OTHER PROCESS OF API MANUFACTURE
MANUFACTURING PROCESS OF M-BROMO ANISOLE
REACTION
PROCESS FLOW DIAGRAM OF M-BROMO ANISOLE
(BATCH 400 KGS)
MANUFACTURING PROCESS OF ETHYL TRIPHENYL PHOSPHONIUM BROMIDE (BATCH 135 KG)
PROCESS FLOW DIAGRAM (BATCH 135 KG)
MANUFACTURING PROCESS OF CINNAMYLALDEHYDE (BATCH 560 KG)
PROCESS FLOW DIAGRAM
MANUFACTURING PROCESS OF M-PHENOXY BENZYL
ALCOHOL (BATCH 175 KG)
PROCESS FLOW DIAGRAM BATCH-175 KG
MANUFACTURING OF BENZYL ALCOHOL BATCH- 187 KGS
PROCESS FLOW DIAGRAM
MATERIAL BALANCE
DISTILLATORY
MANUFACTURING PROCESS OF ALPRAZOLAM
PROCESS FLOW DIAGRAM
MANUFACTURING PROCESS OF METHYLPHENIDATE
PROCESS FLOW DIAGRAM
PRINCIPLES OF PLANT LAYOUT
STORAGE LAYOUT:
EQUIPMENT LAYOUT:
SAFETY:
PLANT EXPANSION:
FLOOR SPACE:
UTILITIES SERVICING:
BUILDING:
MATERIAL-HANDLING EQUIPMENT:
RAILROADS AND ROADS:
MAJOR PROVISIONS IN ROAD PLANNING FOR MULTIPURPOSE SERVICE ARE:
PLANT LOCATION FACTORS
PRIMARY FACTORS
1. RAW-MATERIAL SUPPLY:
2. MARKETS:
3. POWER AND FUEL SUPPLY:
4. WATER SUPPLY:
5. CLIMATE:
SPECIFIC FACTORS
6. TRANSPORTATION:
A. AVAILABILITY OF VARIOUS SERVICES AND PROJECTED RATES
7. WASTE DISPOSAL:
8. LABOR:
9. REGULATORY LAWS:
10. TAXES:
11. SITE CHARACTERISTICS:
12. COMMUNITY FACTORS:
13. VULNERABILITY TO WARTIME ATTACK:
14. FLOOD AND FIRE CONTROL:
EXPLANATION OF TERMS USED IN THE PROJECT REPORT
1. DEPRECIATION:
2. FIXED ASSETS:
3. WORKING CAPITAL:
4. BREAK-EVEN POINT:
5. OTHER FIXED EXPENSES:
6. MARGIN MONEY:
7. TOTAL LOAD:
8. LAND AREA/MAN POWER RATIO:
PROJECT IMPLEMENTATION SCHEDULES
INTRODUCTION
PROJECT HANDLING
PROJECT SCHEDULING
PROJECT CONSTRUCTION SCHEDULE
TIME SCHEDULE
ADDRESSES OF RAW MATERIAL SUPPLIERS
PLANT AND EQUIPMENT SUPPLIERS

APPENDIX – A:

01. PLANT ECONOMICS
02. LAND & BUILDING
03. PLANT AND MACHINERY
04. OTHER FIXED ASSESTS
05. FIXED CAPITAL
06. RAW MATERIAL
07. SALARY AND WAGES
08. UTILITIES AND OVERHEADS
09. TOTAL WORKING CAPITAL
10. TOTAL CAPITAL INVESTMENT
11. COST OF PRODUCTION
12. TURN OVER/ANNUM
13. BREAK EVEN POINT
14. RESOURCES FOR FINANCE
15. INSTALMENT PAYABLE IN 5 YEARS
16. DEPRECIATION CHART FOR 5 YEARS
17. PROFIT ANALYSIS FOR 5 YEARS
18. PROJECTED BALANCE SHEET FOR (5 YEARS)

Additional information

Plant Capacity

250 Kg./Day

Land & Building

(3000 sq.mt.)

Plant & Machinery

US$ 164285

Rate of Return

38%

Break Even Point

42%